Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade

Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly targeted therapies and to identify structural and functional mechanisms for drug response and resistance. Drug development in GIST has successfully exploited the high reliance on KIT/PDGFRA oncogenic signaling as a...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cancer research 2020-10, Vol.26 (19), p.5078-5085
Main Authors: Serrano, César, George, Suzanne
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3
cites cdi_FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3
container_end_page 5085
container_issue 19
container_start_page 5078
container_title Clinical cancer research
container_volume 26
creator Serrano, César
George, Suzanne
description Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly targeted therapies and to identify structural and functional mechanisms for drug response and resistance. Drug development in GIST has successfully exploited the high reliance on KIT/PDGFRA oncogenic signaling as a therapeutic vulnerability. The recent arrival of avapritinib and ripretinib to the GIST arena has aimed to further improve on precision kinase inhibition and address tumor heterogeneity in imatinib-resistant GIST. The two main clinical challenges for the forthcoming years entail tumor eradication in patients with early-stage GIST, and maximization of tumor response in late-stage disease. To succeed, we will need to better understand the mechanisms behind adaptation to KIT inhibition and apoptosis evasion, tumor evolution after successive lines of treatment, and to explore clinically novel creative therapeutic strategies, with the overarching goal to tackle the intrinsic oncogenic complexity while minimizing adverse events.
doi_str_mv 10.1158/1078-0432.CCR-20-1706
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2419084713</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2419084713</sourcerecordid><originalsourceid>FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3</originalsourceid><addsrcrecordid>eNo9kMtOwzAQRS0EoqXwCaAs2aR4HD8SdiiFglSoBGVtOY4DQUkc7ESIv8dVW1Yzc-fOQwehS8BzAJbeABZpjGlC5nn-GhMcg8D8CE2BMREnhLPjkB88E3Tm_RfGQAHTUzQJfRyafIqel8oPztbdYPxQd6qJ3kLZhrgZW-tuo_xTNY3pPoyPVFdG6763bhi7eqiDUlkXqejF_EQLo1VpztFJpRpvLvZxht4f7jf5Y7xaL5_yu1WsKU6HmDBMoaS6zFhCCNFalyAUFxwIF7qoBOWaUZPSQvOiSLO05EVGWEYSBkaYKpmh693e3tnvMXwu29pr0zSqM3b0klDIcEoFJMHKdlbtrPfOVLJ3davcrwQstyTllpLcUpKBpCRBDSTD3NX-xFi0pvyfOqBL_gAnAG48</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2419084713</pqid></control><display><type>article</type><title>Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade</title><source>Freely Accessible Science Journals</source><creator>Serrano, César ; George, Suzanne</creator><creatorcontrib>Serrano, César ; George, Suzanne</creatorcontrib><description>Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly targeted therapies and to identify structural and functional mechanisms for drug response and resistance. Drug development in GIST has successfully exploited the high reliance on KIT/PDGFRA oncogenic signaling as a therapeutic vulnerability. The recent arrival of avapritinib and ripretinib to the GIST arena has aimed to further improve on precision kinase inhibition and address tumor heterogeneity in imatinib-resistant GIST. The two main clinical challenges for the forthcoming years entail tumor eradication in patients with early-stage GIST, and maximization of tumor response in late-stage disease. To succeed, we will need to better understand the mechanisms behind adaptation to KIT inhibition and apoptosis evasion, tumor evolution after successive lines of treatment, and to explore clinically novel creative therapeutic strategies, with the overarching goal to tackle the intrinsic oncogenic complexity while minimizing adverse events.</description><identifier>ISSN: 1078-0432</identifier><identifier>EISSN: 1557-3265</identifier><identifier>DOI: 10.1158/1078-0432.CCR-20-1706</identifier><identifier>PMID: 32601076</identifier><language>eng</language><publisher>United States</publisher><ispartof>Clinical cancer research, 2020-10, Vol.26 (19), p.5078-5085</ispartof><rights>2020 American Association for Cancer Research.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3</citedby><cites>FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3</cites><orcidid>0000-0003-1416-8739</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32601076$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Serrano, César</creatorcontrib><creatorcontrib>George, Suzanne</creatorcontrib><title>Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade</title><title>Clinical cancer research</title><addtitle>Clin Cancer Res</addtitle><description>Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly targeted therapies and to identify structural and functional mechanisms for drug response and resistance. Drug development in GIST has successfully exploited the high reliance on KIT/PDGFRA oncogenic signaling as a therapeutic vulnerability. The recent arrival of avapritinib and ripretinib to the GIST arena has aimed to further improve on precision kinase inhibition and address tumor heterogeneity in imatinib-resistant GIST. The two main clinical challenges for the forthcoming years entail tumor eradication in patients with early-stage GIST, and maximization of tumor response in late-stage disease. To succeed, we will need to better understand the mechanisms behind adaptation to KIT inhibition and apoptosis evasion, tumor evolution after successive lines of treatment, and to explore clinically novel creative therapeutic strategies, with the overarching goal to tackle the intrinsic oncogenic complexity while minimizing adverse events.</description><issn>1078-0432</issn><issn>1557-3265</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNo9kMtOwzAQRS0EoqXwCaAs2aR4HD8SdiiFglSoBGVtOY4DQUkc7ESIv8dVW1Yzc-fOQwehS8BzAJbeABZpjGlC5nn-GhMcg8D8CE2BMREnhLPjkB88E3Tm_RfGQAHTUzQJfRyafIqel8oPztbdYPxQd6qJ3kLZhrgZW-tuo_xTNY3pPoyPVFdG6763bhi7eqiDUlkXqejF_EQLo1VpztFJpRpvLvZxht4f7jf5Y7xaL5_yu1WsKU6HmDBMoaS6zFhCCNFalyAUFxwIF7qoBOWaUZPSQvOiSLO05EVGWEYSBkaYKpmh693e3tnvMXwu29pr0zSqM3b0klDIcEoFJMHKdlbtrPfOVLJ3davcrwQstyTllpLcUpKBpCRBDSTD3NX-xFi0pvyfOqBL_gAnAG48</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Serrano, César</creator><creator>George, Suzanne</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-1416-8739</orcidid></search><sort><creationdate>20201001</creationdate><title>Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade</title><author>Serrano, César ; George, Suzanne</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Serrano, César</creatorcontrib><creatorcontrib>George, Suzanne</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical cancer research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Serrano, César</au><au>George, Suzanne</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade</atitle><jtitle>Clinical cancer research</jtitle><addtitle>Clin Cancer Res</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>26</volume><issue>19</issue><spage>5078</spage><epage>5085</epage><pages>5078-5085</pages><issn>1078-0432</issn><eissn>1557-3265</eissn><abstract>Gastrointestinal stromal tumor (GIST) provides a paradigm to evaluate new molecularly targeted therapies and to identify structural and functional mechanisms for drug response and resistance. Drug development in GIST has successfully exploited the high reliance on KIT/PDGFRA oncogenic signaling as a therapeutic vulnerability. The recent arrival of avapritinib and ripretinib to the GIST arena has aimed to further improve on precision kinase inhibition and address tumor heterogeneity in imatinib-resistant GIST. The two main clinical challenges for the forthcoming years entail tumor eradication in patients with early-stage GIST, and maximization of tumor response in late-stage disease. To succeed, we will need to better understand the mechanisms behind adaptation to KIT inhibition and apoptosis evasion, tumor evolution after successive lines of treatment, and to explore clinically novel creative therapeutic strategies, with the overarching goal to tackle the intrinsic oncogenic complexity while minimizing adverse events.</abstract><cop>United States</cop><pmid>32601076</pmid><doi>10.1158/1078-0432.CCR-20-1706</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-1416-8739</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1078-0432
ispartof Clinical cancer research, 2020-10, Vol.26 (19), p.5078-5085
issn 1078-0432
1557-3265
language eng
recordid cdi_proquest_miscellaneous_2419084713
source Freely Accessible Science Journals
title Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-30T22%3A31%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Gastrointestinal%20Stromal%20Tumor:%20Challenges%20and%20Opportunities%20for%20a%20New%20Decade&rft.jtitle=Clinical%20cancer%20research&rft.au=Serrano,%20C%C3%A9sar&rft.date=2020-10-01&rft.volume=26&rft.issue=19&rft.spage=5078&rft.epage=5085&rft.pages=5078-5085&rft.issn=1078-0432&rft.eissn=1557-3265&rft_id=info:doi/10.1158/1078-0432.CCR-20-1706&rft_dat=%3Cproquest_cross%3E2419084713%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c408t-25041d4cd953222cccd17a6761267cbf746c54e84bc6bb898d6b92592351e7ef3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2419084713&rft_id=info:pmid/32601076&rfr_iscdi=true